Extensive worldwide market potential

 

Every year, millions of people suffer brain damage as a result of critical illnesses such as cardiac arrest or stroke. QuickCool AB has developed a cooling method that uses the nasal cavity’s heat exchange capacities to reduce damage to the brain in critical illnesses.

The company has a CE-marked and clinically-tested product  – the QuickCool® SYSTEM – which cools the body down to <36°C, thereby increasing the chances that patients will survive critical illnesses.

 

The market potential for cooling is extensive and underpenetrated, as many countries have not yet begun to use cooling for the indications: cardiac arrest or difficult-to-treat fever.

We deem that the underpenetrated markets globally have a combined value of approx. SEK 1 billion annually, whereas the overall market potential amounts to several billion SEK, globally.

 

QuickCool AB

Ideon Science Park

Beta 6

Scheelevägen 17

SE-223 70 Lund, Sweden